Antibody-Based Therapeutics for the Treatment of Renal Cell Carcinoma: Challenges and Opportunities.
antibody-based therapies
clinical trials
emerging drugs
immunotherapy
metastatic RCC
renal cell carcinoma
Journal
The oncologist
ISSN: 1549-490X
Titre abrégé: Oncologist
Pays: England
ID NLM: 9607837
Informations de publication
Date de publication:
06 04 2023
06 04 2023
Historique:
received:
08
10
2022
accepted:
28
11
2022
medline:
10
4
2023
pubmed:
7
2
2023
entrez:
6
2
2023
Statut:
ppublish
Résumé
Renal cell carcinoma (RCC) is among the top 10 most common cancers in both men and women with an estimated 75 000 cases each year in the US. Over the last decade, the therapeutic landscape for patients with metastatic RCC has significantly evolved, with immunotherapy emerging as the new front-line therapy. Despite significant improvement in toxicity profile and survival outcomes, key concerns such as patient selection, treatment sequencing, and intrinsic and acquired resistance remain unresolved. Emerging options such as antibody-based therapeutics (eg, anti-CD70, anti-CA9, and anti-ENPP3) are being explored in clinical trials for patients with cancer resistant or refractory to current immunotherapies. Despite positive results for hematological cancers, breast cancer, and more recently bladder cancer, most antibody-based therapies failed to improve the outcomes in patients with advanced RCC. This underscores the need to understand the underlying causes of failed responses to this treatment class, which will ultimately support the rational design of more effective and tolerable treatments. In this review, we summarize the evolving landscape of RCC therapeutics and describe recent clinical trials with emerging antibody-based therapeutics. We also describe the challenges that need to be overcome for the successful creation of therapeutic antibodies for treating RCC.
Identifiants
pubmed: 36745503
pii: 7028682
doi: 10.1093/oncolo/oyac263
pmc: PMC10078913
doi:
Substances chimiques
Antibodies
0
Types de publication
Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
297-308Informations de copyright
© The Author(s) 2023. Published by Oxford University Press.
Références
Lancet. 2016 May 14;387(10032):2008-16
pubmed: 26969090
Cell. 2017 Feb 9;168(4):707-723
pubmed: 28187290
Cancer Chemother Pharmacol. 2019 Jun;83(6):1057-1063
pubmed: 30915497
Mol Cancer. 2022 Jan 18;21(1):20
pubmed: 35042524
Front Oncol. 2020 Sep 04;10:1086
pubmed: 33014768
JAMA Oncol. 2017 Jul 01;3(7):913-920
pubmed: 27787547
Diagn Pathol. 2015 Oct 15;10:189
pubmed: 26470780
N Engl J Med. 2015 Nov 5;373(19):1803-13
pubmed: 26406148
N Engl J Med. 2016 Dec 8;375(23):2246-2254
pubmed: 27718781
Eur Urol. 2016 May;69(5):767-70
pubmed: 26706103
Invest New Drugs. 2020 Dec;38(6):1807-1814
pubmed: 32472319
N Engl J Med. 2021 Apr 8;384(14):1289-1300
pubmed: 33616314
Nanomedicine. 2018 Jan;14(1):123-130
pubmed: 28939491
Cancer Discov. 2017 Sep;7(9):1030-1045
pubmed: 28526733
J Clin Oncol. 2013 Jan 10;31(2):187-94
pubmed: 23213092
Br J Cancer. 2010 Aug 24;103(5):676-84
pubmed: 20664585
Clin Cancer Res. 2007 Mar 15;13(6):1757-61
pubmed: 17363529
Oncologist. 2019 Mar;24(3):366-371
pubmed: 30710066
J Biomed Sci. 2020 Jan 2;27(1):1
pubmed: 31894001
Clin Transl Med. 2021 Mar;11(3):e358
pubmed: 33783991
N Engl J Med. 2018 Jul 5;379(1):64-73
pubmed: 29972754
Cancer Res. 1991 May 15;51(10):2694-8
pubmed: 2021947
Clin Cancer Res. 2022 Apr 14;28(8):1540-1548
pubmed: 35140121
Cancer Med. 2020 Feb;9(3):1152-1160
pubmed: 31829518
Proc Natl Acad Sci U S A. 1999 Mar 16;96(6):3137-42
pubmed: 10077650
Clin Cancer Res. 2016 Apr 15;22(8):1989-99
pubmed: 26589436
Nature. 2016 Nov 3;539(7627):112-117
pubmed: 27595394
Biochem Soc Trans. 2016 Jun 15;44(3):951-9
pubmed: 27284065
Nat Rev Dis Primers. 2017 Mar 09;3:17009
pubmed: 28276433
Nucl Med Biol. 1996 Oct;23(7):873-9
pubmed: 8971854
J Clin Oncol. 1995 Mar;13(3):688-96
pubmed: 7884429
J Immunol. 2005 Jan 15;174(2):710-7
pubmed: 15634890
N Engl J Med. 2012 Mar 8;366(10):883-892
pubmed: 22397650
Nat Commun. 2022 Jan 20;13(1):405
pubmed: 35058437
Lancet. 2019 Jun 15;393(10189):2404-2415
pubmed: 31079938
N Engl J Med. 2021 Sep 16;385(12):1091-1103
pubmed: 34161051
Nat Rev Urol. 2019 Sep;16(9):539-552
pubmed: 31278395
Oncologist. 2020 Nov;25(11):981-992
pubmed: 32860288
Nat Med. 2001 Sep;7(9):987-9
pubmed: 11533692
Br J Cancer. 1999 Oct;81(4):741-6
pubmed: 10574265
Nat Rev Drug Discov. 2017 May;16(5):315-337
pubmed: 28303026
Clin Cancer Res. 2020 Feb 15;26(4):793-803
pubmed: 31727677
Am J Hematol. 2019 May;94(S1):S3-S9
pubmed: 30680780
N Engl J Med. 2019 Mar 21;380(12):1116-1127
pubmed: 30779529
Nat Med. 2020 Oct;26(10):1519-1530
pubmed: 33020645
Science. 2005 Jan 7;307(5706):58-62
pubmed: 15637262
J Extracell Vesicles. 2021 Apr;10(6):e12079
pubmed: 33850608
Eur Urol. 2013 Sep;64(3):478-85
pubmed: 22980441
Front Pharmacol. 2020 May 08;11:619
pubmed: 32457618
Mol Cancer Ther. 2013 Jul;12(7):1245-54
pubmed: 23657946
Biologics. 2019 May 01;13:33-51
pubmed: 31118560
J Immunother Cancer. 2018 Dec 10;6(1):145
pubmed: 30526680
Microvasc Res. 1990 Sep;40(2):246-63
pubmed: 2250603
N Engl J Med. 2021 Nov 25;385(22):2036-2046
pubmed: 34818478
Int J Cancer. 1993 Mar 12;53(5):829-36
pubmed: 8449608
Sci Rep. 2016 Aug 03;6:30988
pubmed: 27484008
Cell Rep. 2019 May 21;27(8):2411-2425.e9
pubmed: 31116985
Oncologist. 2021 Feb;26(2):e290-e297
pubmed: 32918790
Hum Pathol. 2012 Sep;43(9):1394-9
pubmed: 22401771
J Urol. 2006 Jan;175(1):57-62
pubmed: 16406869
Neuro Oncol. 2018 Jan 10;20(1):55-65
pubmed: 28651374
Cancer Immunol Res. 2014 Jul;2(7):598-605
pubmed: 24990240
Expert Rev Mol Diagn. 2020 Feb;20(2):141-150
pubmed: 31498685
Am J Pathol. 1999 Jul;155(1):267-74
pubmed: 10393858
Adv Mater. 2021 Dec;33(49):e2103471
pubmed: 34665481
Clin Cancer Res. 2020 Jun 1;26(11):2582-2594
pubmed: 31980465
Cell. 1993 May 7;73(3):447-56
pubmed: 8387892
N Engl J Med. 2018 Apr 05;378(14):1277-1290
pubmed: 29562145
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
Cell Rep. 2018 Apr 3;23(1):313-326.e5
pubmed: 29617669
Cancer Discov. 2020 Jan;10(1):40-53
pubmed: 31732494
J Med Chem. 2019 Aug 8;62(15):6876-6893
pubmed: 31282155
Mol Cancer. 2016 Feb 02;15:10
pubmed: 26831905
Nat Genet. 2013 Jun;45(6):580-5
pubmed: 23715323
J Biol Chem. 2014 Feb 7;289(6):3571-90
pubmed: 24311787
Crit Rev Oncol Hematol. 2021 May;161:103331
pubmed: 33862248
Nat Rev Clin Oncol. 2018 Feb;15(2):81-94
pubmed: 29115304
Adv Ther. 2021 Dec;38(12):5662-5670
pubmed: 34664194
N Engl J Med. 2007 Jan 11;356(2):115-24
pubmed: 17215529
Diagnostics (Basel). 2020 Dec 02;10(12):
pubmed: 33276608
Mol Ther. 2013 Apr;21(4):904-12
pubmed: 23423337
Mol Biosyst. 2013 Jun;9(6):1220-33
pubmed: 23511837
Methods Mol Biol. 2012;901:277-93
pubmed: 22723108
Korean J Pathol. 2013 Oct;47(5):426-32
pubmed: 24255630
Clin Cancer Res. 2007 Jan 15;13(2 Pt 2):709s-715s
pubmed: 17255298
Eur Urol. 2011 Oct;60(4):615-21
pubmed: 21741761
Kidney Int. 2002 Jul;62(1):237-44
pubmed: 12081583
J Immunother Cancer. 2020 Aug;8(2):
pubmed: 32817395
Eur Urol. 2018 Sep;74(3):257-260
pubmed: 29730017
J Clin Pathol. 2015 Jan;68(1):12-7
pubmed: 25315900
Int J Mol Sci. 2020 Apr 05;21(7):
pubmed: 32260578
Nat Biomed Eng. 2021 Sep;5(9):1084-1098
pubmed: 34616047
Cancers (Basel). 2021 Sep 09;13(18):
pubmed: 34572755
Oncotarget. 2016 Dec 27;7(52):86999-87015
pubmed: 27894104
Tumour Biol. 2014 Dec;35(12):12131-7
pubmed: 25142236
N Engl J Med. 2019 Mar 21;380(12):1103-1115
pubmed: 30779531
Mol Cancer Ther. 2016 Dec;15(12):2946-2954
pubmed: 27671527
Diagnostics (Basel). 2019 Aug 14;9(3):
pubmed: 31416266
Int J Cancer. 2002 Mar 20;98(3):352-6
pubmed: 11920585
J Am Acad Dermatol. 2020 Nov;83(5):1239-1253
pubmed: 32461079
J Am Soc Nephrol. 2005 Apr;16(4):1126-34
pubmed: 15744000
Cancer. 2019 Apr 1;125(7):1124-1132
pubmed: 30624766
Br J Cancer. 2004 Mar 8;90(5):985-90
pubmed: 14997194
Br J Cancer. 2016 Jan 12;114(1):63-70
pubmed: 26671750
Front Immunol. 2019 Jun 07;10:1296
pubmed: 31231397
Immunity. 2016 May 17;44(5):989-1004
pubmed: 27192565
Curr Opin Oncol. 2019 May;31(3):216-221
pubmed: 30747736
J Cell Physiol. 2012 Feb;227(2):658-67
pubmed: 21465472
J Extracell Vesicles. 2021 Jun;10(8):e12112
pubmed: 34188786
Br J Cancer. 2006 Aug 7;95(3):298-306
pubmed: 16892042
Expert Opin Biol Ther. 2018 Sep;18(9):947-957
pubmed: 30124333
EBioMedicine. 2017 May;19:31-38
pubmed: 28408240
Lancet. 2008 Aug 9;372(9637):449-56
pubmed: 18653228
Cancer Res. 2006 Feb 15;66(4):2328-37
pubmed: 16489038
J Extracell Vesicles. 2020 Mar 11;9(1):1736935
pubmed: 32284825
J Clin Oncol. 2006 May 1;24(13):e20-2
pubmed: 16648493
Oncogene. 2018 Mar;37(12):1561-1575
pubmed: 29321659
Front Oncol. 2020 Oct 28;10:582843
pubmed: 33194717
Proc Natl Acad Sci U S A. 2011 Sep 13;108(37):15336-41
pubmed: 21873242
J Clin Oncol. 2002 Jan 1;20(1):289-96
pubmed: 11773181
Lancet Oncol. 2019 Oct;20(10):1370-1385
pubmed: 31427204
Nat Biotechnol. 2020 Feb;38(2):233-244
pubmed: 31907405
J Extracell Vesicles. 2022 Jan;11(1):e12179
pubmed: 34982509
Cell. 2020 Oct 1;183(1):269-283.e19
pubmed: 32916130
Cancer Res. 2000 Dec 15;60(24):7075-83
pubmed: 11156414
Oncologist. 2021 Mar;26(3):182-e361
pubmed: 33289953
Eur Urol. 2019 Aug;76(2):151-156
pubmed: 31151678
Investig Clin Urol. 2020 Jul;61(4):372-381
pubmed: 32665993
Cancer Res. 2005 Dec 1;65(23):10952-8
pubmed: 16322243
Expert Rev Proteomics. 2018 Mar;15(3):259-275
pubmed: 29343144
Nat Rev Drug Discov. 2019 Aug;18(8):585-608
pubmed: 31175342
Am J Surg Pathol. 2007 Mar;31(3):371-81
pubmed: 17325478
J Urol. 2005 Jun;173(6):2150-3
pubmed: 15879877
Urol Oncol. 2017 Aug;35(8):507-515
pubmed: 28551412